<DOC>
	<DOCNO>NCT02855944</DOCNO>
	<brief_summary>The purpose study determine patient ovarian , fallopian tube , primary peritoneal cancer best respond treatment rucaparib versus chemotherapy .</brief_summary>
	<brief_title>ARIEL4 : A Study Rucaparib Versus Chemotherapy BRCA Mutant Ovarian , Fallopian Tube , Primary Peritoneal Cancer Patients</brief_title>
	<detailed_description>Rucaparib orally available , small molecule inhibitor poly-adenosine diphosphate [ ADP ] ribose polymerase ( PARP ) develop treatment ovarian cancer associate homologous recombination ( HR ) DNA repair deficiency ( HRD ) . The safety efficacy rucaparib evaluate several Phase 1 Phase 2 study . An oral formulation focus current development effort . Rucaparib currently investigate monotherapy patient cancer associate breast cancer susceptibility gene 1 ( BRCA1 ) BRCA2 mutation . While PARP inhibitor demonstrate consistent robust clinical activity patient relapse ovarian cancer associate HRD , prospective study evaluate efficacy safety PARPi versus standard care chemotherapy limit . The primary purpose Phase 3 study compare efficacy safety rucaparib versus chemotherapy treatment relapse ovarian cancer patient deleterious BRCA1/2 mutation tumor .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Rucaparib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Be 18 year age time informed consent form sign Have histologically confirm Grade 2 Grade 3 endometrioid epithelial ovarian , fallopian tube , primary peritoneal cancer Received â‰¥ 2 prior chemotherapy regimen relapse progressive disease confirm radiologic assessment Have biopsiable evaluable disease . Note : biopsy optional patient know harbor BRCA1/2 mutation Have sufficient archival formalinfixed paraffinembedded ( FFPE ) tumor tissue available planned analysis History prior cancer except curatively treat , evidence cancer currently ( provide chemotherapy complete &gt; 6 month prior and/or bone marrow transplant &gt; 2 year prior first dose rucaparib ) . Prior treatment PARP inhibitor Symptomatic and/or untreated central nervous system metastases Preexisting duodenal stent and/or gastrointestinal disorder defect would , opinion Investigator , interfere absorption rucaparib Women pregnant breast feed Hospitalization bowel obstruction within 3 month prior enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>peritoneal cancer</keyword>
	<keyword>platinum sensitive</keyword>
	<keyword>relapse disease</keyword>
	<keyword>PARP Inhibitor</keyword>
	<keyword>PARP</keyword>
	<keyword>rucaparib</keyword>
	<keyword>ruca</keyword>
	<keyword>homologous recombination</keyword>
	<keyword>homologous recombination deficiency</keyword>
	<keyword>genomic scarring</keyword>
	<keyword>loss heterozygosity</keyword>
	<keyword>CO-338</keyword>
	<keyword>PF-01367338</keyword>
	<keyword>PF 01367338</keyword>
	<keyword>CO-338-043</keyword>
	<keyword>platinum sensitive ovarian cancer</keyword>
	<keyword>platinum sensitive fallopian tube cancer</keyword>
	<keyword>platinum sensitive primary peritoneal cancer</keyword>
	<keyword>platinum sensitive peritoneal cancer</keyword>
	<keyword>gynecological cancer</keyword>
	<keyword>Clovis</keyword>
	<keyword>Clovis oncology</keyword>
	<keyword>ARIEL2</keyword>
	<keyword>ARIEL 2</keyword>
	<keyword>ARIEL-2</keyword>
	<keyword>ARIEL-3</keyword>
	<keyword>ARIEL 3</keyword>
	<keyword>ARIEL3</keyword>
	<keyword>ARIEL4</keyword>
	<keyword>ARIEL-4</keyword>
	<keyword>ARIEL 4</keyword>
	<keyword>A4</keyword>
	<keyword>advanced OC</keyword>
	<keyword>platinum resistant ovarian cancer</keyword>
	<keyword>platinum resistant primary ovarian cancer</keyword>
	<keyword>Rubraca</keyword>
</DOC>